Biometrics: May 2014

Salutron, Inc. Introduces Its New LifeTrak App

FREMONT, Calif., May 22, 2014 /PRNewswire/ -- Salutron, Inc., the foremost leader in heart-rate monitoring and precise biometric data acquisition, today introduced its new LifeTrak app for both Android and iOs – a breakthrough app that provides a comprehensive view of your health and fitness vitals. The LifeTrak app syncs with your LifeTrak Zone C410 or LifeTrak Move C300 device to give you a deeper understanding of your activity, sleep patterns and most importantly your overall well-being – giving you more motivation to stay on track with a healthy lifestyle.

Synchronizing data between your LifeTrak activity tracker and your smartphone has never been easier with the new LifeTrak app. The app gives you more detailed, 24/7 insight into data trends on a daily, weekly, and yearly basis and provides easy-to-read data graphs that keep you organized and motivated toward your health and fitness goals.

Knowing and tracking your heart rate is the most important step toward improving your overall well-being, which is why LifeTrak's line of activity trackers help you "Follow your Heart" to a better lifestyle. LifeTrak activity monitors incorporate heart rate and physical motion into the calorie burn calculation, which is considered a more precise way to determine calorie expenditure. They also provide the most sophisticated science and accurate data calculation of any activity tracker on the market, giving users the ability to make more informed changes to their health.

The combination of the LifeTrak app working in tandem with its activity trackers makes the experience of personal health and fitness monitoring uniquely efficient and automated. LifeTrak activity trackers allow users to track all of their vitals (including sleep) and view up to 7 days of data, right on their wrists. With the LifeTrak app, users can extend the data storage capabilities to weeks, months or years. Additional features of the LifeTrak app include:

Fitness dashboard with intuitive graphical progress circle- heart rate, steps, distance, calories, active time, sleep, and workout See your data trends, goals and progress at a hourly, daily, weekly, monthly and yearly level Rotate to landscape for one, detailed chart that integrates heart rate, steps, calories and distance Precise Actigraphy – Displays active time, sedentary time, and sleep time details Ability to sync with your LifeTrak activity tracker at a press of the button"We are very proud of the customer response to our popular line of LifeTrak activity trackers, so introducing this new app was a natural next step for us," said Mike Tsai, CEO of Salutron. "Adding the LifeTrak app to our portfolio only serves to enhance our ability to provide a fully automated, ubiquitous experience for our customers, so that they can easily attain a healthier lifestyle."

LifeTrak is a free app available today for both Android and iPhone devices. To download the app and check device compatibility, visit www.lifetrakusa.com/app or follow us on Twitter and Facebook.

About Salutron, Inc.

Salutron, Inc., is an industry leader in heart rate monitoring technology for fitness and health equipment and products. Found in gyms across the globe, the company's technology is incorporated into many name brands including, Precor, Nautilus, Star Trac, and Life Fitness. From the gym to your wrist, Salutron also offers accurate, durable and connected wearable devices for physiological monitoring on-the-go.

The wearable devices, in band and watch format, are branded under LifeTrak and SmartHealth. Salutron technology has also been incorporated into many well-known private label brands including Timex, Reebok, New Balance, Sportline and Pro-Form. Products with Salutron's technology can be found in major retailers including Sports Authority, Sport Chalet, Dick's Sporting Goods, Big 5, Best Buy, RadioShack, Frys, Target, Walmart, Walgreens, CVS, Costco, and Amazon.

Additionally, Salutron develops physiological monitoring products for government agencies like DARPA, NASA, the US Army, and brings those innovative technologies to the everyday consumer. Salutron is privately held and based in Fremont, CA. More information on Salutron and LifeTrak products can be found at lifetrakusa.com or follow @MyLifeTrak.

Media Contact for Salutron:

April Mayrath
Consort Partners
salutron@consortpartners.com
Tel: +1 210 323 7018

SOURCE Salutron, Inc.

RELATED LINKS
http://www.lifetrakusa.com

reade more...

Xencor to Present at Jefferies 2014 Global Healthcare Conference

MONROVIA, Calif., May 22, 2014 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced that Bassil Dahiyat, Ph.D., president and chief executive officer, will present at the Jefferies 2014 Global Healthcare Conference on Thursday, June 5, 2014 at 8:00 a.m. EDT in New York City, NY.

A live audio webcast of the presentation will be available on the "Events and Presentations" section in the Investors section of the company's website located at http://investors.xencor.com/events.cfm. A replay of the presentation will be posted on the Xencor website approximately one hour after the event and will be available for 30 days following the presentation.

About Xencor, Inc.
Xencor is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer. Currently, six candidates are in clinical development internally and with partners that have been engineered with Xencor's XmAb® technology. Xencor's internally-discovered programs include XmAb5871 in Phase 1b/2a clinical trials for the treatment of Rheumatoid arthritis and lupus, XmAb7195 in preclinical development for the treatment of asthma, and XmAb5574/MOR208 which has been licensed to Morphosys AG and is in Phase 2 clinical trials for the treatment of acute lymphoblastic leukemia and non-Hodgkin lymphoma. Xencor's XmAb antibody engineering technology enables small changes to the structure of monoclonal antibodies resulting in new mechanisms of therapeutic action. Xencor partners include Amgen, Merck, Janssen R&D LLC, Alexion and Boehringer Ingelheim.

For more information, please visit www.xencor.com.

SOURCE Xencor

ClinCapture 2.0 Official Launch on May 23rd

SUNNYVALE, Calif., May 20, 2014 /PRNewswire-iReach/ -- On May 23rd at 10am PST Marc Desgrousilliers, Chief Technology Officer at Clinovo, will introduce the new 2.0 version of ClinCapture, the most advanced open source Electronic Data Capture (EDC) system. Marc will give a one-hour online demonstration of the new features in ClinCapture 2.0. He will focus on ClinCapture's new On Demand Trainings, Rules Studio, and Interactive Dashboards. Registration for the webinar is now open on clinovo.com/clincapture2.

The 2.0 ClinCapture release includes a new Rules Studio to create edit checks within the EDC system without XML programming. The Rules Studio does not require any specific training or IT expertise.ClinCapture 2.0 becomes the first open source EDC system with a fully integrated drag-and-drop edit check builder.

The new Interactive Dashboards give users a graphical overview of essential metrics directly from ClinCapture's homepage. Users can quickly dip in and out of their clinical data to manage different clinical sites or monitor new queries. The dashboards are easily customizable thanks to the drag-and-drop interface.

ClinCapture 2.0 features online self-paced On Demand Trainings. The convenience of online format accelerates the adoption of ClinCapture worldwide and helps facilitate the learning curve. "The online trainings save the time of flying out trainers, and thus break down the barrier to learning ClinCapture in different time zones," explains Danny Lieberman, CEO of Israel-based Clear Clinica.

The release comes with a series of additional enhancements, making ClinCapture more user-friendly coupled with increased capability. In particular, the extended import and export capabilities make the extracted data directly readable in SAS. The migration of data from another EDC system to ClinCapture is also simplified by this enhanced import capability.

The Clinovo team will showcase ClinCapture 2.0 at major industry conferences in the weeks following the online launch. Clinovo will be presenting its flagship EDC system at the Partnerships in Medical Device Conference from June 2nd to 4th in Chicago (IL), and DIA from June 15th to 19th in San Diego (CA).

Since its launch in 2008, ClinCapture has been deployed for clinical studies from five patients to tens of thousands of patients. Three sponsor companies have secured FDA approvals using ClinCapture as their preferred Electronic Data Capture (EDC) system. A 30-day evaluation of ClinCapture can be started on clinovo.com/clincapture.

Contact information
Sophie McCallum
Director of Operations, Clinovo
408-773-6258
sophie.mccallum(at)clinovo(dot)com

About Clinovo

Clinovo is a technology focused Contract Research Organization (CRO) headquartered in the Silicon Valley. Clinovo streamlines clinical trials for life science companies globally by developing validated, intuitive open source eClinical Systems. Clients claim over 50% cost savings using Clinovo's open source Electronic Data Capture (EDC) system ClinCapture, and CDISC Express, the first open source CDISC conversion tool. Services also include Clinical Data Services, Staffing Solutions, and TechTrainings.

Media Contact: Sophie McCallum, Clinovo, 4087736258, sophie.mccallum@clinovo.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com

SOURCE Clinovo

Medbox Chief Executive Officer to Appear on Bloomberg TV's "In the Loop with Betty Liu" on May 20, 2014

LOS ANGELES, May 20, 2014 /PRNewswire-USNewswire/ -- Medbox, Inc. (OTCQB: MDBX) (www.medbox.com), a leader in providing ancillary services to the alternative medicine industry, dispensary consulting services, and patented medicine dispensing systems to medical and retail industries, today announced that Dr. Bruce Bedrick, chief executive officer of Medbox, will appear on Bloomberg TV's "In the Loop with Betty Liu" on May 20, 2014 at 9:35 am ET.

Dr. Bedrick has been invited to appear to discuss Medbox and its dispensing and storage systems, along with recent headlines regarding the legalized business of marijuana. Medbox is the industry leader in the legal marijuana industry. The Company has consulted with more than 400 clients in six states, helping businesses secure licenses, identify locations, build-out dispensaries, educate patients and conduct business in a safe, secure, and legally compliant way.

About Betty Liu:

Betty Liu is editor-at-large for Bloomberg Television and the host of "In the Loop with Betty Liu," a weekday program providing the fastest and most comprehensive coverage of the headlines and major events set to shape the business day ahead. She also hosts "In the Loop, At the Half" on Bloomberg Radio, airing weekdays at noon. An award-winning business journalist, Liu regularly interviews influential business, political and media leaders including Warren Buffett, Carlos Slim, Ted Turner and Lloyd Blankfein. Before joining Bloomberg Television, Liu served as an anchor for CNBC Asia based in Hong Kong. Prior to that, she was the Atlanta bureau chief for the Financial Times. Earlier in her career, Liu was the Taiwan bureau chief for Dow Jones Newswires - the youngest ever in Asia - and a Hong Kong-based regional correspondent for the newswire. In 1997, she received a Dow Jones Newswires Award for her coverage of the Asian financial crisis.

About Medbox, Inc.:?

Medbox is a leader in the development, sales and service of automated, biometrically controlled dispensing and storage systems for medicine and merchandise. Headquartered in Los Angeles, Medbox, through its wholly owned subsidiary, Medicine Dispensing Systems, offers their patented systems, software and consulting services to pharmacies, alternative medicine dispensaries and local governments in the U.S. In addition, through its wholly owned subsidiary, Vaporfection International, Inc. (www.vaporfection.com), the company offers an industry award winning medical vaporizer product. Medbox, through its newly established subsidiaries, is in development of the following ancillary services catered to the alternative medicine industry: merchant services and armored transport for cash deposits, cannabidiol research and development, real estate acquisitions and subsequent lease programs to alternative medicine dispensaries, and alternative medicine dispensary management services.

Forward-Looking Statements: The statements in this press release constitute forward-looking statements within the meaning of federal securities laws.? Such statements are based on our current beliefs and expectations and are inherently subject to significant business, economic and competitive uncertainties and contingencies, many of which are beyond our control.? In addition, such forward-looking statements are subject to assumptions with respect to future business strategies and decisions that are subject to change.? Potential risks and uncertainties include, but are not limited to, technical advances in the industry, political conditions and economic conditions in the states considering such legislation.? We do not take any obligation to update any forward-looking statement to reflect events or developments after a forward-looking statement was made.

Medbox, Inc. is a publicly traded company, and is quoted on the OTCQB, ticker symbol MDBX.

For more information on Medbox, please contact the Medbox Investor Relations Department at (800) 762-1452 or go online to www.medbox.com.

Contacts:

Investors
Stephen Hart
Hayden IR
+1- 917-658-7878
hart@haydenir.com

SOURCE Medbox, Inc.

Retailer Keeps Loss Prevention Low and Customer Satisfaction High with DigitalPersona Fingerprint Solution

Trusted partner for biometric identity verification solutions. (PRNewsFoto/DigitalPersona, Inc.)jwplayer.key="2kY/GKwZ2uQZmDlQ9VYArfZt2b4+KhHX3+DM4zisgtE=";REDWOOD CITY, Calif., May 21, 2014 /PRNewswire/ -- DigitalPersona, Inc., a trusted partner for biometric identity verification solutions, today announced that New Look, a leading China fashion retailer, has selected a Point-of-Sale (POS) system enabled with DigitalPersona® fingerprint technology. After a successful trial at six of the retailer's stores in February 2014, New Look is set to expand their use of biometrics in 16 of its stores by the end of 2014 — with longer-range plans to equip 100 stores by 2017. The retailer initially selected biometric technology as an alternative to passwords for improving time and attendance accuracy, but found it also enhances loss prevention and customer service.

Each New Look store has two to four POS terminals depending on the store size, which are shared by the retailer's employees. In the past, the potential for employees to clock in for each other existed, increasing the risk of payroll fraud. Prior to adopting fingerprint biometrics, New Look implemented six-digit passwords to enhance security. However, passwords were cumbersome for employees to remember and had to be changed every 90 days to meet security standards. As a result, the IT department at New Look's UK-based headquarters saw an uptick in the number of calls to reset forgotten passwords.

New Look employees now use their fingerprints to clock in and log on to the POS terminals, providing a more secure alternative to passwords. In turn, store managers and deputy managers must use their fingerprints to approve returns, discounts and overrides.

"We have seen customer service levels improve because employees are more efficient since they no longer have to remember complex passwords," said Sky Shen, senior IT consultant at New Look. "Biometrics has helped us stay below our one percent loss prevention standard since fingerprints are also now used for management authorization of overrides."

Incorporating biometrics to confirm positive identity creates a business advantage for retailers, such as New Look, which hopes to attract more franchise owners and open more stores as part of its expansion plans in China. New Look China is also considering recommending deployment at their UK headquarters.

"DigitalPersona's biometric solutions are assisting retailers worldwide in their efforts to reduce fraud, keep loss prevention rates low and improve customer service," said Richard Agostinelli, DigitalPersona president and CEO. "We're very pleased with the success that New Look, through their partnership with Cegid Group, has experienced with our technology and look forward to their continued growth."

See DigitalPersona at Retail Asia Expo in Cegid Group Booth #L35, June 10-12 in Hong Kong.

About DigitalPersona
DigitalPersona offers the world's broadest portfolio of biometrics-based identity verification solutions. Applications range from highly secure banking environments and complex government identity programs to point-of-sale retail systems. Our solutions verify the identity of more than 200 million authorized users worldwide and significantly reduce the risk of fraud, theft and unauthorized access. Offerings for end-users and system integrators include industry-specific software applications, complete SDKs and a full range of optical, silicon, touch, swipe and embedded readers. For more information call +1 650.474.4000 or send an email to pr@digitalpersona.com.

© 2014 DigitalPersona, Inc. All rights reserved. DigitalPersona® is a trademark of DigitalPersona, Inc. registered in the United States and other countries. All other trademarks are the property of their respective owners.

Logo - http://photos.prnewswire.com/prnh/20140515/88123

SOURCE DigitalPersona, Inc.

RELATED LINKS
http://www.digitalpersona.com

reade more...

Texas' Biocorridor continues to grow exponentially with addition of mixed use community

BRYAN/COLLEGE STATION, Texas, May 19, 2014 /PRNewswire/ -- ATLAS is the first master planned community in Texas designed for companies engaged in manufacturing biologics and pharmaceuticals.

Less than two miles from Texas A&M University, ATLAS offers a prime location for a community with an amenity-rich lifestyle and the collaborative atmosphere companies need with access to world-class researchers and students.

ATLAS will provide a vibrant, walkable lifestyle for the people relocating to Bryan/College Station to work in the biotech and pharmaceutical labs and offices.

Texas A&M is under construction on the newly formed Center for Innovation in Advanced Development and Manufacturing (CIADM). The first component is a $91 million facility operated by KALON Biotherapeutics that will manufacture a Glaxo Smith Kline product and provide a national response capability in the event of a pandemic.

This national asset is situated near Caliber Biotherapeutics, the world's largest plant-based vaccine manufacturing facility. Also under construction is the global headquarters for Nutrabolt, the maker of Cellucor nutrition products.

An important part of the experience within ATLAS is a thriving town center where residents and guests can walk to Lake Atlas and enjoy the inviting green space. Also in planning are a boutique hotel, retail, waterfront restaurants, and a live music venue. ATLAS also has direct access to amenities of Traditions Club, which features a Nicklaus designed golf course and is home to the Texas A&M golf teams.

"We are developing ATLAS specifically for life-science manufacturers who want to position their companies and people in a truly integrated community where it's possible to work, collaborate, live and recreate, all at the epicenter of the region's burgeoning One Health Plus Biocorridor," stated Spencer Clements, Principal, Traditions Acquisition Partnership, developer of Atlas and The Traditions Club and Community.

"To successfully attract additional biotech industry, our quality of life amenities have to be competitive," College Station Mayor, Nancy Berry said.

"As the biocorridor grows, this entire region of Texas will benefit," echoed Bryan, Texas Mayor, Jason Bienski. "To see BCS and the Research Valley become the new biotech development area of choice is truly exciting."

"The Atlas announcement represents another brilliant step in accomplishing the Biocorridor vision. We are honored to work day in and day out with a development partner that desires to compete with us on the global playing field. I know Atlas will be world-class." stated Todd E. McDaniel, President & CEO, The Research Valley Partnership, Inc.

For more information, atlastx.com

SOURCE Atlas, Texas; Biocorridor

reade more...

IBM Receives Frost & Sullivan Customer Value Leadership Award for its Mobile Identity and Access Management Solutions

MOUNTAIN VIEW, Calif., May 20, 2014 /PRNewswire/ -- Based on its recent analysis of mobile authentication, Frost & Sullivan recognizes IBM with the 2014 Global Frost & Sullivan Award for Customer Value Leadership. Central to the company's success in generating value for customers is the integration of various mobile security, mobile identity, and access management solutions. IBM's strong value proposition with regards to the provisioning of context-based authentication for multiple mobile device types and mobile applications has also been instrumental to its success.

"When it comes to identity and access management, organizations often face a trade-off between improving security levels and delivering greater end-user convenience," said Frost & Sullivan Senior Industry Analyst Mario Fernandez. "IBM breaks the security/end-user convenience trade-off through its IBM Security Access Manager for Mobile appliance."

The IBM Security Access Manager for Mobile appliance's risk engine determines the risk of an end user's authentication attempt by comparing it with a historical behavior profile of that user, which contains information related to the volume, type and frequency of transactions; Internet protocol reputation; geographic location; and device fingerprinting. On ascertaining the risk, the appropriate authentication method is applied. While low-risk access attempts require simple authentication methods such as a password, high-risk access attempts might involve hardware or software one-time password tokens.

To determine the appropriate authentication method, the IBM Security Access Manager for Mobile risk engine also pays heed to the application or data that the end user wants to access. For instance, if an end user wants to access a business-critical application or confidential data, then they must use an authentication method with a high degree of irrefutability. Essentially then, security becomes context-based and organizations can establish—and seamlessly enforce—access management policies without introducing greater end-user inconvenience.

The value proposition of IBM's Security Access Manager for Mobile appliance is enhanced through the integration of other IBM products, including IBM Security Access Manager for Web, which adds content security capabilities to protect against attacks such as SQL injection and cross-site scripting. Likewise, IBM's Federated Identity Manager, which supports the Security Assertion Markup Language (SAML), WS-Federation and OpenID standard protocols, can enable federated single sign-on. This facilitates the integration of cloud services, such as Google Apps or Office 365, which also support the above-mentioned protocols.

In a bid to remain ahead of its competitors, IBM added two important security companies and their corresponding products to its portfolio in 2013—Trusteer and Fiberlink. The company has also drawn up a future-proof product roadmap that recognizes that biometric authentication methods and contactless technologies will play a prominent role in enabling mobile access.

"Already, IBM's scientists have developed an algorithm to determine biometric-based authentication risk scores and risk analysis that can be incorporated into IBM Security Access Manager for Mobile," said Fernandez.

Each year, Frost & Sullivan presents this award to the company that demonstrates excellence in implementing strategies that proactively create value for its customers with a focus on improving the return on the investment that customers make in its services or products. This award recognizes the company's inordinate focus on enhancing the value that its customers receive, beyond simply good customer service, leading to improved customer retention and, ultimately, customer base expansion.

Frost & Sullivan Best Practices Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis and extensive secondary research to identify best practices in the industry.

About IBM Security

IBM Security offers one of the most advanced and integrated portfolios of enterprise security products and services. The portfolio, supported by world-renowned IBM X-Force research and development, provides the security intelligence to help organizations protect their people, data, applications and infrastructure. IBM offers security solutions for identity and access management, database security, application development, risk management, endpoint management, next-generation intrusion protection and more. IBM operates one of the world's broadest security research and development, and delivery organizations. IBM monitors 15 billion security events per day in more than 130 countries and holds more than 3,000 security patents. For more information on IBM security solutions, X-Force reports, and webinars, please visit: www.ibm.com/security.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants. For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies? Contact us: Start the discussion.

Contact:

Mireya Espinoza
P: 210. 247.3870
F: 210.348.1003
E: mireya.espinoza@frost.com

Jacqueline McCouat
P: + 44 7768 504084
E: jacqueline.mccouat@uk.ibm.com

SOURCE Frost & Sullivan

Digital Wallets Designed for Eliminating the Need for Credit Cards - NXTD's Wocket™ Looks to Change the Way Consumers Make Credit Card Payments Worldwide

CORAL SPRINGS, Florida, May 20, 2014 /PRNewswire/ --

Smart Technology continues to evolve in the biometrics sector as advanced technologies become available for today's consumer looking for secured methods of future credit card payments: NXT-ID Inc. (OTCBB: NXTD), Apple Inc. (NASDAQ: AAPL), Yahoo! Inc. (NASDAQ: YHOO), Google Inc. (NASDAQ: GOOG) and Microsoft Corporation (NASDAQ: MSFT)

In an exclusive Q&A, Mr. Verdi discusses recent ventures including new movie deals and his investments in game-changing technologies, including Apple and biometric mobile security company NXT-ID Inc., (OTCQB: NXTD) (OTCBB: NXTD), which is currently preparing to launch its smart wallet, the Wocket™, (http://www.wocketwallet.com) with advance orders starting May 28th.

Interview Highlights with Mr. Verdi:

Question:
This past year has already seen you reach some key milestones; making movies with the best in Hollywood, like Martin Scorsese and your investment in NXTD is up over 300 percent in less than a year. What are you most excited about for the balance of this year?

A: Chad A. Verdi
Well, that's a tough one. I guess I am the most excited about NXTD right now, only because they are about to launch the Wocket™ this month. Wocket™ is a smart wallet with a re-programmable single credit card device that operates under a secured system using biometrics.

I feel it will change the way people make credit card payments worldwide. Everyone is trying to get in on this game with mobile payments, mobile wallets, mobile apps like LOOP and COIN. Everyone is trying to figure out the best way to do it. I think Wocket™ has the right approach; separate from your phone. Most people are concerned about what happens if they lose their phone or it gets stolen - what happens with all that payment info on your phone? With Wocket™, it's not a worry because after each transaction it basically goes back to a blank card. Your identity and payment info are safe!

It's great to think I originally invested in this a few years ago and now it may become the leader in the payment sector that I thought it would!

To read the full Chad A. Verdi interview, please click here:http://www.fnmprofiles.com/profiles-nxtd.html

Question:
In terms of your investments, you invest in both large companies like Apple (NASDAQ: AAPL) and Yahoo (NASDAQ: YHOO) and other big tech and entertainment companies but you also take risks and invest in smaller companies with emerging technology like NXTD. Where do you see the biggest potential pay-off?

A: Chad A. Verdi
I obviously wish I would have had the opportunity to get into Apple from the beginning. I would have bet big on it, just like I have with NXTD. Companies that take a different path from what the competition is doing represent the biggest opportunity, if it works. Steve Jobs set the course for Apple, I still love the company but it's hard to know if the vision will stay intact. NXTD is still young and they are taking a revolutionary approach to payments and identity issues, very different from their competitors and I like that.

About Chad A. Verdi:

Mr. Verdi is an established movie producer and businessman with an interest in technology investments. He will be the executive producer of three films with Oscar-winning director, Martin Scorcese. The casts of these films will include names such as Liam Neeson, Andrew Garfield, Miles Teller, Aaron Eckhart and Adam Driver.

Smart Technology News and Notes:

In other smart technology news around the markets, Google Inc. (NASDAQ: GOOG) and Microsoft Corporation (NASDAQ: MSFT) have also been in the news for their recent developments. Google recently made their famed Google Glass available for the general public for a short amount of time and continue to make developments improving the technology, with the latest move allowing Glass wearers to spend money Bitcoin. Microsoft, on the other hand, is rumored to be developing a smart watch experts say could give both Samsung and Apple a run for their money.

FinancialNewsMedia.com is leading provider of third party publishing & news dissemination services. If you would like more information regarding our news coverage solutions, please visit http://www.financialnewsmedia.com for more details. Get an edge on the market with our Premium News Alerts that are FREE for a limited time at http://www.financialnewsmedia.com/. Follow us on Facebook: http://www.facebook.com/financialnewsmedia and Twitter:http://twitter.com/FNMgroup.

DISCLAIMER: FN Media Group LLC (FNMG) is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNMG is NOT affiliated in any manner with any company mentioned herein. FNMG and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNMG's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. FNMG is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. FFor current services performed FNMG has been compensated one thousand four hundred dollars for news coverage of the current press release issued by NXT-Id, Inc. by a non-affiliated third party.

FNMG HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNMG undertakes no obligation to update such statements.

Contact Information:
Company: FN Media Group, LLC
Contact email: editor@financialnewsmedia.com
U.S. Phone: 1(954)345-0611
URL: http://www.financialnewsmedia.com

Source: FN Media Group

SOURCE FN Media Group, LLC

reade more...

Power-hungry audio and video analytic applications have met their match with next-generation ultra-low-power DSP from TI

Texas Instruments Logo. (PRNewsFoto/Texas Instruments Incorporated)jwplayer.key="2kY/GKwZ2uQZmDlQ9VYArfZt2b4+KhHX3+DM4zisgtE=";DALLAS, May 20, 2014 /PRNewswire/ -- Today, Texas Instruments (TI) (NASDAQ: TXN) introduces the next-generation, ultra-low-power DSP in TI's scalable TMS320C5000™ device portfolio, the TMS320C5517 (C5517). The new DSP delivers up to 200 MHz performance enabling faster processing of data with low-power consumption for demanding applications, such as audio and video, biometrics and other analytic specific applications. These applications are opening up a world of possibilities that add capabilities such as face detection, object tracking and voice recognition to a new generation of smart products. Along with the improved performance, the C5517 DSP also offers a compelling combination of low stand-by and low active power, making it the best choice for battery-powered, portable systems requiring analytics.

Scaling the C5000 DSP portfolio

With the addition of this full-featured C5517 DSP, TI now offers a scalable C5000™ device portfolio with lower performance (50/100 MHz) C5535 DSPs to mid-range (120/150 MHz) C5514/15 DSPs and now high performance with the newest C5517 DSP (200 MHz).

Features and benefits of the C5517 DSP:

Enable external sensor connectivity. The McSPI enables low-power analytics through connectivity to external sensors. It operates in master or slave modes, as well as adds to the standard SPI ports on the device to support greater serial connectivity. Connect to standard codecs such as EICs D/A, A/D and more. McBSP is a flexible serial port that allows customers to connect to standard codecs. It also enables continuous full-duplex communication and supports up to 128 channels in TDM mode. Simplify communication between processors. The Universal Host Port Interface (UHPI) is an easy way for a host processor to connect to the DSP while allowing direct access to the DSPs memories for sharing of data between elements. Build smaller hardware for space-constrained applications. Customers can pack signal processing performance into systems with challenging space and power restrictions due to the C5517 DSPs small 10x10 footprint and ultra-low power operation. Enhance and extend product lines. The C5517 DSP offers a greater number and variety of peripherals and greater signal processing performance than previous members of TI's ultra-low-power DSP family. This enables developers to add new capabilities or improve analytic performance of an existing product line, while leveraging the same tool and software basis previously used.Simplifying development with a scalable software solution

The new C5517 DSP is software compatible with previous C5000 devices, which allows existing customers to easily take advantage of the new features and 200 MHz operation. In addition to software compatibility, TI offers a complete tool chain which includes a full chip support library that customers can use to start their designs. C5517 DSP customers also have access to tips from TI's experienced partners and active TI E2E™ communities from whom they can get advice, recommendations and support for their designs. For example, one of the third-party developers, SNAP Sensor technology, helps turn TI's C5517 DSP into a machine vision solution with their specific hardware, software and vision module.

"The C5517 solution enables rapid development and customization of vision sensing applications. Working with TI allowed us to create a cost and power optimized people sensing and information extraction solution," said Pascal Nussbaum, SNAP Sensor CTO. "The SNAP Suite development environment facilitates quick and easy vision application development on a video stream powered by the C5517 DSP. This SNAP Sensor module will be available in June."

Availability and pricing

TI's C5517 EVM is available now through TI distribution partners or TI.com for $499 and includes a TPS65023 integrated power management step-down converter to manage the power. Additionally, the silicon is sampling now for $9.05/1KU.

For more information:

About Texas Instruments

Texas Instruments Incorporated (TI) is a global semiconductor design and manufacturing company that develops analog ICs and embedded processors. By employing the world's brightest minds, TI creates innovations that shape the future of technology. TI is helping more than 100,000 customers transform the future, today. Learn more at www.ti.com.

Trademarks

TMS320C5000, C5000 and TI E2E are trademarks of Texas Instruments Incorporated. All trademarks are the property of their respective owners.

SOURCE Texas Instruments

Coherus BioSciences erhält $ 55 Millionen Serie-C-Finanzierung

Coherus BioSciences Logo. (PRNewsFoto/Coherus BioSciences)jwplayer.key="2kY/GKwZ2uQZmDlQ9VYArfZt2b4+KhHX3+DM4zisgtE=";REDWOOD CITY, Kalifornien, 19. Mai 2014 /PRNewswire/ -- Coherus BioSciences, Inc. („Coherus"), ein führendes Biopharmaunternehmen mit dem Schwerpunkt auf Biosimilars, gab heute den Abschluss einer Serie-C-Preferred-Investitionsrunde in H?he von $ 55 Millionen bekannt. Die neuen Investoren KKR & Co. L.P. („KKR"), Venrock, RA Capital Management, Rock Springs Capital und Fidelity Biosciences schlossen sich bei dieser Transaktion den bestehenden Investoren Sofinnova Ventures, Lilly Ventures und Vivo Capital an.

„Wir sind sehr erfreut, dass wir das Vertrauen und die finanzielle Unterstützung einer so au?erordentlichen Gruppe von Investoren im Gesundheitsbereich erhalten", sagte Denny Lanfear, President und CEO von Coherus. „Seit seiner Gründung vor vier Jahren hat Coherus ausgezeichnete Fortschritte bei der Verwirklichung seiner Ziele gemacht, biosimilare Biologika in Phase-III-Studien und auf den Markt zu bringen. Die von unseren Investoren bereitgestellten Kapitalmittel erm?glichen es uns, mit unseren Entwicklungspl?nen fortzufahren, unsere Partnerschaftsstrategien zu optimieren und den Patienten wichtige Therapien schneller bereitzustellen."

Im Rahmen dieser Transaktion wird Ali Satvat, Direktor im Team für Investition in das Gesundheitssegment von KKR, in den Aufsichtsrat von Coherus berufen. „Wir sind sehr froh, Denny und sein erfahrenes Team bei ihren Wachstumsinitiativen unterstützen zu k?nnen, die den Markt für Biologika transformieren werden", sagte Mr. Satvat. „Wir glauben, dass die Plattform von Coherus sehr gut positioniert ist, um mit ihrer Produktpipeline und ihren soliden wissenschaftlichen und technischen F?higkeiten erfolgreich zu sein."

Seit seiner Gründung hat Coherus über $ 220 Millionen Finanzmittel von Kapitalgebern, über nicht verw?ssernde Lizenzgebühren sowie über Meilensteine erhalten.

Uber Coherus BioSciences, Inc.

Coherus Biosciences ist ein führendes Biopharmaunternehmen mit dem Schwerpunkt auf Biosimilars, das Patienten weltweit den Zugang zu lebensver?ndernden Arzneimitteln erleichtert. Das Unternehmen hat seinen Firmensitz in der San Francisco Bay Area und wurde von Biotech-Pionieren gegründet, die schon beim Aufbau der ersten Generation amerikanischer Biotherapeutika-Unternehmen mitgewirkt hatten. Coherus hat ein auf Kooperation basierendes Gesch?ftsmodell entwickelt, das sich auf ein strategisches Konsortium von Dienstleistern stützt, die über Eigentumsverh?ltnisse und gemeinsame Initiativen miteinander verbunden sind. Zu den weltweiten Marketingpartnern z?hlen führenden Biopharma-Unternehmen in Europa, Asien und Lateinamerika.

Biosimilars sind für die Behandlung einer Reihe chronischer und oft lebensbedrohender Krankheiten anstelle bestehender biologischer Markenpr?parate vorgesehen und sie haben das Potenzial, Kosten zu reduzieren und einer gr??eren Anzahl von Patienten den Zugriff darauf zu erm?glichen. Weitere Informationen finden Sie unter www.coherus.com.

Kontakt – Beth Jimison – bjimison@coherus.com +1-650-649-3526

Logo - http://photos.prnewswire.com/prnh/20120507/SF01448LOGO

SOURCE Coherus BioSciences, Inc.

RELATED LINKS
http://www.coherus.com

reade more...

Coherus BioSciences réunit 55 millions de dollars dans le cadre d'un financement de série C

Coherus BioSciences Logo. (PRNewsFoto/Coherus BioSciences)jwplayer.key="2kY/GKwZ2uQZmDlQ9VYArfZt2b4+KhHX3+DM4zisgtE=";REDWOOD CITY, Californie, 19 mai 2014 /PRNewswire/ -- Coherus BioSciences, Inc. (« Coherus »), une des plus grandes sociétés de plate-forme de médicaments biologiques qui concentre ses activités autour des biosimilaires, a annoncé aujourd'hui la fin d'un cycle de financement privilégié de série C qui a permis de réunir 55 millions de dollars. Pour cette transaction, les nouveaux investisseurs KKR & Co. L.P. (KKR), Venrock, RA Capital Management, Rock Springs Capital et Fidelity Biosciences ont rejoint les investisseurs existants, à savoir Sofinnova Ventures, Lilly Ventures et Vivo Capital.

« Nous sommes très heureux d'avoir la confiance et le soutien financier d'un groupe aussi extraordinaire d'investisseurs dans les soins de santé », explique Denny Lanfear, PDG de Coherus. « Depuis sa création il y a quatre ans, Coherus a engrangé des succès impressionnants dans la réalisation de son objectif qui consiste à faire entrer les biosimilaires dans des essais de phase 3 et sur le marché. Les ressources de capital fournies par nos investisseurs nous permettront de poursuivre nos projets de développement, d'optimiser nos stratégies de partenariat et de proposer plus rapidement des thérapies essentielles aux patients ».

Dans le cadre de cette transaction, Ali Satvat, directeur de l'équipe d'investissement dans le soins de santé de KKR, rejoindra le conseil d'administration de Coherus. « Nous nous réjouissons à l'idée de soutenir Denny et son équipe expérimentée pour leurs initiatives de croissance visant à transformer le marché des médicaments biologiques », selon M. Satvat. « Nous pensons que la plate-forme de Coherus est bien positionnée pour réussir compte tenu de son pipeline de produits et de ses robustes capacités scientifiques et techniques ».

Depuis sa création, Coherus a réuni plus de 220 millions de dollars en fonds propres et en redevances de licence non dilutives et jalons de licence.

A propos de Coherus BioSciences, Inc.

Coherus est une des plus grandes entreprises de plate-forme de médicaments biologiques qui s'attache à proposer des thérapies biosimilaires de haute qualité que accroîtront l'accès des patients à des médicaments qui changent la vie à travers le monde. Avec son siège dans la région de la baie de San Francisco et fondée par un groupe de pionniers de la biotechnique qui ont contribué à créer le secteur des biothérapies de première génération aux Etats-Unis, Coherus a mis au point un modèle d'entreprise collaboratif qui se fonde sur un consortium stratégique de fournisseurs de services regroupés par la propriété et des initiatives partagées. Les partenariats mondiaux de commercialisation de Coherus font intervenir des entreprises biopharmaceutiques de tout premier niveau en Europe, en Asie et en Amérique latine.

Les biosimilaires doivent remplacer les médicaments biologiques de marque actuels en vue de traiter une gamme élargie de maladies chroniques et mettant souvent en jeu le pronostic vital, avec le potentiel de réduire les coûts et de renforcer l'accès des patients. Pour de plus amples informations, veuillez consulter www.coherus.com.

Contact – Beth Jimison – bjimison@coherus.com +1-650-649-3526

Logo - http://photos.prnewswire.com/prnh/20120507/SF01448LOGO

SOURCE Coherus BioSciences, Inc.

RELATED LINKS
http://www.coherus.com

reade more...

Coherus BioSciences asegura una financiación de serie C de 55 millones de dólares

REDWOOD CITY, California, 19 de mayo de 2014 /PRNewswire/ -- Coherus BioSciences, Inc. ("Coherus"), una compa??a de plataforma biol?gica centrada en biosimilares, ha anunciado hoy el cierre de una ronda de inversi?n de serie C preferente que asciende a 55 millones de d?lares. Los nuevos inversores KKR & Co. L.P. ("KKR"), Venrock, RA Capital Management, Rock Springs Capital y Fidelity Biosciences se unieron a los inversores existentes Sofinnova Ventures, Lilly Ventures y Vivo Capital en la transacci?n.

"Estamos muy contentos de tener la confianza y soporte financiero de un grupo de inversores de salud tan extraordinario", dijo Denny Lanfear, director general y consejero delegado de Coherus. "Desde su fundaci?n hace cuatro a?os, Coherus ha realizado un excelente progreso en sus objetivos de trasladar los biol?gicos biosimilares a ensayos de fase 3 y al mercado. Los recursos de capital ofrecidos por nuestros inversores nos permitir?n seguir nuestros planes de desarrollo, optimizar nuestras estrategias de asociaci?n y ofrecer terapéuticos esenciales a los pacientes m?s r?pido".

Como parte de la transacci?n, Ali Satvat, director del equipo de inversi?n en salud de KKR, se unir? a la junta directiva de Coherus. "Estamos encantados de apoyar a Denny y a su veterano equipo en sus iniciativas de crecimiento para transformar el mercado de la biolog?a", dijo Satvat. "Creemos que la plataforma Coherus est? bien posicionada para el éxito dada su l?nea de proyecto de productos y sus fuertes capacidades cient?ficas y técnicas".

Desde su creaci?n, Coherus ha recaudado m?s de 220 millones de d?lares de tasas de licencia de valor y no dilutivas e hitos.

Acerca de Coherus BioSciences, Inc.

Coherus Biosciences es una destacada compa??a de plataforma biol?gica centrada en el suministro de terapéuticos biosimilares de alta calidad que ampliar?n el acceso de los pacientes a los medicamentos que cambian la vida en todo el mundo. Con sede en el ?rea de la Bah?a de San Francisco y fundada por medio de un grupo de pioneros en biotecnolog?a que han ayudado a construir la industria bioterapéutica de primera generaci?n de América, Coherus ha desarrollado un modelo empresarial colaborador ?nico que mejora el consorcio estratégico de los principales proveedores de servicios alineados por medio de la propiedad e incentivos compartidos. Las asociaciones de comercializaci?n globales de Coherus incluyen las principales compa??as biofarmacéuticas de primer nivel en Europa, Asia y Latinoamérica.

Los biosimilares est?n pensados para su uso en lugar los biol?gicos de marca existentes para el tratamiento de enfermedades cr?nicas y que a menudo suponen una amenaza para la vida, y cuentan con potencial para reducir los costes y ampliar el acceso a los pacientes. Si desea m?s informaci?n, visite la p?gina web www.coherus.com.

Contacto – Beth Jimison – bjimison@coherus.com +1-650-649-3526

Logo - http://photos.prnewswire.com/prnh/20120507/SF01448LOGO

SOURCE Coherus BioSciences, Inc.

RELATED LINKS
http://www.coherus.com

reade more...

Coherus BioSciences Secures $55 million Series C Financing

Coherus BioSciences Logo. (PRNewsFoto/Coherus BioSciences)jwplayer.key="2kY/GKwZ2uQZmDlQ9VYArfZt2b4+KhHX3+DM4zisgtE=";REDWOOD CITY, Calif., May 19, 2014 /PRNewswire/ -- Coherus BioSciences, Inc. ("Coherus"), a leading biologics platform company focused on biosimilars, announced today the closing of a Series C Preferred investment round raising $55 million. New investors KKR & Co. L.P. ("KKR"), Venrock, RA Capital Management, Rock Springs Capital and Fidelity Biosciences joined existing investors Sofinnova Ventures, Lilly Ventures and Vivo Capital in the transaction.

"We are very pleased to have the confidence and financial support of such an extraordinary group of health care investors," said Denny Lanfear, President and CEO of Coherus. "Since its founding four years ago, Coherus has made excellent progress on its goals of moving biosimilar biologics into Phase 3 trials and onto the market. The capital resources provided by our investors will allow us to prosecute our development plans, optimize our partnering strategies and deliver essential therapeutics to patients faster."

As part of the transaction, Ali Satvat, Director on KKR's health care investing team, will join the Board of Directors of Coherus. "We are excited to support Denny and his experienced team on their growth initiatives to transform the biologics market," said Mr. Satvat. "We believe that the Coherus platform is well-positioned to succeed given its product pipeline and strong scientific and technical capabilities."

Since its inception, Coherus has raised over $220 million from equity and non-dilutive licensing fees and milestones.

About Coherus BioSciences, Inc.

Coherus is a leading biologics platform company focused on delivering high-quality biosimilar therapeutics that will expand patient access to life-changing medications worldwide. Headquartered in the San Francisco Bay Area and founded by a group of biotech pioneers who helped build America's first generation biotherapeutics industry, Coherus has developed a collaborative business model that leverages a strategic consortium of service providers aligned through ownership and shared incentives. Coherus' global commercialization partnerships include top-tier biopharma companies in Europe, Asia, and Latin America.

Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and expand patient access. For additional information, please visit www.coherus.com.

Contact – Beth Jimison – bjimison@coherus.com 650.649.3526

Logo - http://photos.prnewswire.com/prnh/20120507/SF01448LOGO

SOURCE Coherus BioSciences, Inc.

RELATED LINKS
http://www.coherus.com

reade more...

Coherus BioSciences se asegura US$55 millones de financiación de Serie C

CIUDAD DE REDWOOD, California, 19 de mayo de 2014 /PRNewswire/ -- Coherus BioSciences, Inc. ("Coherus"), una importante compa??a de plataforma biol?gica dedicada a los biosimilares, anunci? hoy el cierre de una rueda de inversi?n Preferente de Serie C que recaud? US$55 millones. Los nuevos inversores KKR & Co. L.P. ("KKR"), Venrock, RA Capital Management, Rock Springs Capital y Fidelity Biosciences se unieron en la operaci?n a los inversores existentes, Sofinnova Ventures, Lilly Ventures y Vivo Capital.

"Estamos muy felices de tener la confianza y el apoyo financiero de este extraordinario grupo de inversores del sector de la salud", dijo Denny Lanfear, Presidente y CEO de Coherus. "Desde su fundaci?n hace cuatro a?os, Coherus ha realizado un excelente progreso en sus objetivos de hacer avanzar los biol?gicos biosimilares hacia ensayos de Fase 3 y hacia el mercado. Los recursos financieros que proveen nuestros inversores nos permitir?n avanzar con nuestros planes de desarrollo, optimizar nuestras estrategias de sociedades y brindar a los pacientes terapéuticas esenciales, con mayor velocidad".

Como parte de la operaci?n, Ali Satvat, Director del equipo de inversi?n en cuidado de la salud de KKR, se unir? a la Junta Directiva de Coherus. "Nos emociona apoyar a Denny y a su experimentado equipo en sus iniciativas de crecimiento para transformar el mercado de biol?gicos", dijo Satvat. "Creemos que la plataforma de Coherus est? bien posicionada para triunfar teniendo en cuenta su oferta de productos y su solidez cient?fica y técnica".

Desde su creaci?n, Coherus ha recaudado m?s de US$220 millones a partir de capital y comisiones por licenciamientos no convertibles.

Acerca de Coherus BioSciences, Inc.

Coherus Biosciences es una importante compa??a de plataforma biol?gica centrada en el suministro de terapéuticos biosimilares de alta calidad que ampliar? el acceso de los pacientes a medicamentos revolucionarios en todo el mundo. Con sede en el ?rea de la Bah?a de San Francisco y fundada por un grupo de pioneros en biotecnolog?a que ayudaron a construir la industria bioterapéutica de primera generaci?n de Estados Unidos, Coherus ha desarrollado un modelo comercial de colaboraci?n ?nico que aprovecha el consorcio estratégico de proveedores de servicios alineados por medio de la propiedad e incentivos compartidos. Las asociaciones de comercializaci?n globales de Coherus incluyen compa??as biofarmacéuticas de primer?simo nivel en Europa, Asia y América Latina.

Los biosimilares est?n concebidos para ser usados en lugar de los biol?gicos de marca existentes para el tratamiento de una variedad de enfermedades cr?nicas –a menudo mortales– que cuentan con potencial para reducir los costos y ampliar el acceso de los pacientes. Si desea informaci?n adicional, s?rvase visitar www.coherus.com.

Contacto – Beth Jimison – bjimison@coherus.com +1-650-649-3526

Logo - http://photos.prnewswire.com/prnh/20120507/SF01448LOGO

FUENTE Coherus BioSciences, Inc.

SOURCE Coherus BioSciences, Inc.

RELATED LINKS
http://www.coherus.com

reade more...

Fingerprint Cards Acquires Anacatum Design

GOTHENBURG, Sweden, May 19, 2014 /PRNewswire/ --

Fingerprint Cards (FPC) has acquired all outstanding shares of Anacatum Design AB (Anacatum), a Linkoping-based Swedish technology licensing and ASIC developing company. FPC has previously announced that it has licensed Anacatum's industry-leading Analog to Digital Converter (ADC) technology and used the ASIC development services provided by Anacatum in the development of FPC's touch and swipe fingerprint sensors.

Anacatum is as of today an owned subsidiary of FPC. The acquisition price for Anacatum will not be disclosed.

Johan Carlstr?m, President and CEO at FPC, comments: "This acquisition provides FPC with world-leading technology that will further strengthen our intellectual property portfolio. FPC also gains access to leading analog IP and ASIC development competencies and, by integrating Anacatum's development team into FPC, we will further accelerate our development of the industry's most ambitious portfolio of touch and swipe fingerprint sensors for the mobile devices industry. We are very much looking forward to welcoming the Anacatum team into FPC."

Lars-Erik Nordell, Chairman of the Board of Anacatum, comments: "We are very pleased to see this step for Anacatum. Through its leading technology and highly skilled engineering team, Anacatum will make a great contribution to FPC. As the leading fingerprint biometric sensor company, FPC will be the perfect home for Anacatum's technology and employees."

Rolf Sundblad, CTO and Managing Director of Anacatum Design AB, comments: "This acquisition marks the continuation of the strong collaboration FPC has had with Anacatum since Anacatum was founded and the start of a new phase when Anacatum becomes fully integrated with FPC. We will bring our patented ADC technology into FPC as well as a team of highly skilled engineers and we are very much looking forward to creating even more competitive technology while being a part of FPC."

About Fingerprint Cards AB (publ)

Fingerprint Cards AB (FPC) markets, develops and produces biometric components and technologies that through the analysis and matching of an individual's unique fingerprint verify the person's identity. The technology consists of biometric sensors, processors, algorithms and modules that can be used separately or in combination with each other. The competitive advantages offered by the FPC's technology include unique image quality, extreme robustness, low power consumption and complete biometric systems. With these advantages and the ability to achieve extremely low manufacturing costs, the technology can be implemented in volume products such as smart cards and mobile phones, where extremely rigorous demands are placed on such characteristics. The company's technology can also be used in IT and Internet security, access control, etc.

Fingerprint Cards AB (publ) discloses this information pursuant to the Swedish Securities Market Act (2007:528) and the Swedish Financial Instruments Trading Act (1991:980). The information was issued for publication on May 19, 2014 at 08.00 am CET.

Important information

Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the constituent information in accordance with the rules and regulations prevailing in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any of the company's securities in any jurisdiction.

For more information contact: Johan Carlstr?m, CEO Fingerprint Cards AB (publ), +46-(0)31-60-78-20, investrel@fingerprints.com

SOURCE Fingerprint Cards AB

reade more...

Coherus BioSciences garante financiamento Série C de US$ 55 milhões

Coherus BioSciences Logo. (PRNewsFoto/Coherus BioSciences)jwplayer.key="2kY/GKwZ2uQZmDlQ9VYArfZt2b4+KhHX3+DM4zisgtE=";REDWOOD CITY, Calif?rnia, 19 de maio de 2014 /PRNewswire/ -- A Coherus BioSciences, Inc. ("Coherus"), empresa de plataforma l?der focada em produtos biol?gicos biossimilares, anunciou hoje o fechamento de uma rodada de investimento preferencial Série C arrecadando US$ 55 milh?es. Os novos investidores KKR & Co. L.P. ("KKR"), Venrock, RA Capital Management, Rock Springs Capital e Fidelity Biosciences unem-se aos investidores atuais Sofinnova Ventures, Lilly Ventures e Vivo Capital na transaç?o.

"Estamos muito contentes por termos a confiança e o apoio financeiro de um grupo t?o extraordin?rio de investidores em assistência à sa?de", disse Denny Lanfear, presidente e CEO da Coherus. "Desde a sua fundaç?o, h? quatro anos, a Coherus tem tido um excelente progresso em seus objetivos de mudança de biol?gicos biossimilares em testes de Fase 3 para o mercado. Os recursos de capital fornecidos por nossos investidores nos permitir?o processar nossos planos de desenvolvimento, otimizar nossas estratégias de parceria e fornecer produtos terapêuticos essenciais para os pacientes mais rapidamente."

Como parte da transaç?o, Ali Satvat, diretor da equipe de investimento em assistência à sa?de da KKR, ir? unir-se ao Conselho de Administraç?o da Coherus. "Estamos muito animados para apoiar Denny e sua equipe experiente em suas iniciativas de crescimento para transformar o mercado de produtos biol?gicos", disse Satvat. "Acreditamos que a plataforma da Coherus est? bem posicionada para ter sucesso devido à sua linha de produtos e forte capacidade cient?fica e técnica."

Desde a sua criaç?o, a Coherus j? arrecadou mais de US$ 220 milh?es de participaç?o patrimonial e taxas de licenciamento n?o dilu?das e marcos determinantes.

Sobre a Coherus BioSciences, Inc.

A Coherus é uma importante empresa de plataforma de produtos biol?gicos focada na distribuiç?o de produtos terapêuticos biossimilares de alta qualidade, que ir?o expandir o acesso dos pacientes a medicamentos que salvam vidas em todo o mundo. Sediada na ?rea da Ba?a de S?o Francisco e fundada por um grupo de pioneiros da biotecnologia, que ajudaram a construir a primeira geraç?o do setor de produtos bioterapêuticos, a Coherus desenvolveu um modelo de neg?cios colaborativo ?nico, que alavanca um cons?rcio estratégico de provedoras de serviços essenciais, alinhadas em termos de propriedade e incentivos compartilhados. As parcerias de comercializaç?o mundial da Coherus incluem empresas biofarmacêuticas de primeira linha na Europa, ?sia e América Latina.

Os biossimilares s?o usados como substitutos de produtos biol?gicos de marca no mercado, para tratar uma variedade de doenças crônicas e frequentemente fatais, com a possibilidade de reduzir custos e expandir o acesso dos pacientes. Para mais informaç?es, por favor, acesse www.coherus.com.

Contato – Beth Jimison – bjimison@coherus.com +1-650-649-3526

Logo - http://photos.prnewswire.com/prnh/20120507/SF01448LOGO

FONTE Coherus BioSciences, Inc.

SOURCE Coherus BioSciences, Inc.

RELATED LINKS
http://www.coherus.com

reade more...

Human Identification Market worth $804.0 Million by 2018

DALLAS, April 14, 2014 /PRNewswire/ --

According to the new market research report "Human Identification Market by Technology (Next Generation Sequencing, Rapid DNA Analysis, Capillary Electrophoresis, PCR), Application (Forensics, Paternity Testing), DNA Amplification, Quantification, Extraction, Services, & Software - Forecast to 2018", published by MarketsandMarkets, The global Human Identification Market was valued at an estimated $419.4 Million in 2013 and is expected to reach $804.0 Million by 2018, growing at a CAGR of 13.9% between 2013 and 2018.

Browse 108 market data tables and 19 figures spread through 240 Pages and in-depth TOC on "Human Identification Market"

http://www.marketsandmarkets.com/Market-Reports/human-identification-market-100607777.html

Early buyers will receive 10% customization on this report.

The report segments this market based on technology, application, products and services, and geography. Among various technologies, the capillary electrophoresis commanded the largest share in 2013, while next generation sequencing (NGS) is forecasted to be the fastest-growing segment in the human identification market. Factors such as rising awareness regarding new technologies for the DNA analysis, government support in the form of funding, and the need to reduce time and cost associated with DNA analysis are driving the growth of human identification market. Furthermore, owing to continuous advancements in technology, new and innovative products are being launched in the market which is another major factor providing impetus for growth of the market.

Based on geography, the global Human Identification Market is segmented into North America, Europe, Asia, and the Rest of the World (RoW). North America accounted for the largest share of the market in 2013. This large share of the North American region can be attributed various factors including expansion of the U.S. national DNA database and government support in the form of grants and funds.

The prominent players in the Human Identification Market are Thermo Fisher Scientific, Inc. (U.S.), Promega Corporation (U.S.), QIAGEN N.V. (The Netherlands), and Illumina (U.S.).

Browse related reports

Genomics Market by Products - [Instruments (NGS platform, Microarray, RT-PCR), Consumables (Genechips, Reagents for DNA Extraction & Purification, Sequencing)], Services (Sequencing & Microarray Services, and Software) - Global Forecast to 2018
http://www.marketsandmarkets.com/Market-Reports/genomics-market-613.html

Gene Expression Analysis Market by Technology (DNA Microarray, Real-Time PCR, Next Generation Sequencing), Consumables (DNA Chips, Reagents), Services (Gene Profiling, Bioinformatics, Data Analysis Software) & Applications] - Global Forecast to 2018

http://www.marketsandmarkets.com/Market-Reports/gene-expression-analysis-market-156613968.html

About MarketsandMarkets

MarketsandMarkets is a global market research and consulting company based in the U.S. We publish strategically analyzed market research reports and serve as a business intelligence partner to Fortune 500 companies across the world.

MarketsandMarkets also provides multi-client reports, company profiles, databases, and custom research services. MarketsandMarkets covers thirteen industry verticals, including advanced materials, automotive and transportation, banking and financial services, biotechnology, chemicals, consumer goods, energy and power, food and beverages, industrial automation, medical devices, pharmaceuticals, healthcare IT semiconductor and electronics, and telecommunications and IT.

We at MarketsandMarkets are inspired to help our clients grow by providing apt business insight with our huge market intelligence repository.

Contact:
Mr. Rohan
North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas, TX 75252
Tel: +1-888-600-6441
Email: sales@marketsandmarkets.com

Visit MarketsandMarkets Blog http://www.marketsandmarketsblog.com/market-reports/healthcare/biotechnology
Connect with us on LinkedIn @ http://www.linkedin.com/company/marketsandmarkets

SOURCE MarketsandMarkets

reade more...

emaratech and SRI to Expand Use of Biometrics in the United Arab Emirates, Jordan and Oman

MENLO PARK, Calif., May 14, 2014 /PRNewswire/ -- SRI International has entered into an exclusive reseller agreement with emaratech, the leading information technology solutions provider and management consulting company for commercial and government entities throughout the United Arab Emirates (UAE) and Jordan. The reseller agreement is non-exclusive in Oman. As a result of this strategic relationship, SRI's next-generation Iris on the Move® (IOM) biometric product line is now available for airport security, border patrol and a broad range of related security applications in the regions.

"Evolving and increasingly complex security challenges require cutting edge technologies that can be installed and deployed in diverse indoor and outdoor environments," said Thani Alzaffin, director general and board member, emaratech. "SRI's proven biometric products operate at the leading edge, and for that reason our strategic partners will benefit from this new teaming relationship."

SRI's award-winning IOM biometric systems combine the unprecedented accuracy of iris recognition with quick, convenient solutions for secure access control and identity authentication. Unlike other biometric readers that require users to stop or to position their eyes close to a camera, IOM products allow people to simply glance and go.

"emaratech has rapidly and effectively deployed biometric systems for demanding, high-traffic security environments in the UAE," said Mark Clifton, vice president, Products and Services Division at SRI International. "Aligning SRI's cutting-edge iris recognition products with emaratech's experience installing and supporting biometric solutions will allow organizations to dramatically enhance their security posture."

SRI's end-to-end IOM biometric product line rapidly performs highly accurate identity authentication effortlessly at a distance and on the move in all lighting conditions. IOM products are optimally suited for airports, border patrol and similar security applications, and include systems for indoor and outdoor operation.

About emaratech
emaratech (emarat technology solutions), owned by the Investment Corporation of Dubai, is a technology and management consulting company that provides high-end market strategies, outsourced technology and advanced business information technology solutions for both private and public sectors. Services include system integration, applications development, business analysis and consulting, infrastructure hosting, process re-engineering, business process, consultancy, quality management, call centers, quality assurance and managed services.

emaratech delivers key organizational and business intelligence services to enable governments and institutional organizations to operate efficiently and effectively, also to minimize bureaucracy, streamline costs and increase revenues through effective business solutions. emaratech is renowned for its business domain knowledge in the areas of border access & control (electronic gates at UAE, Oman and Jordan International Airports) payment technologies (noqodi), government electronic services, security services, ERP implementation and real estate technology solutions.

About SRI International
SRI International is a nonprofit research and innovation center headquartered in Silicon Valley. Government and business clients worldwide come to SRI for pioneering solutions in biomedical sciences and health, chemistry and materials, computing, education, economic development, energy, security and defense, robotics, sensing, and more. We provide research, laboratory and advisory services, technology development and licenses, deployable systems, products, and venture opportunities. Our innovations have created new industries and marketplace value, and lasting benefits to society. Visit SRI's website and Timeline of Innovation to learn more.

Photo - http://photos.prnewswire.com/prnh/20140513/87376

SOURCE SRI International

Two of World's Busiest Airports Deploy Biometric Automated Passport Control Kiosks; Global Market to Grow 22% CAGR from 2014 - 2018

DENVER, May 12, 2014 /PRNewswire/ -- Earlier this month, Atlanta Hartsfield-Jackson and Chicago O'Hare -- two of the world's busiest airports -- announced the introduction of biometric Automated Passport Control (APC) kiosks.

According to Maxine Most, Principal at Acuity Market Intelligence, "APC kiosks offer a cost effective and rapidly deployable means of reducing congestion at international arrivals. These announcements reflect a decisive global trend towards expediting international airport passengers through rapid adoption of automated border control technology."

Acuity Market Intelligence's latest research "The Global Automated Border Control Industry Report: Airport eGates and Kiosks" projects North American and European airports will drive a global APC Kiosk market of nearly 8,000 units and more than $550 million in revenues by 2018, reflecting a 22% CAGR over five years.

"Currently, less than 400 APC kiosks have been deployed in 13 airports in the US and Canada," says Most, a biometric identity and security technology expert. "APC kiosk numbers will grow rapidly as they migrate globally to Europe, Asia, and the Middle East. Though North America currently represents 100% of the APC Kiosk market, by 2018 Europe will dominate with 42% market share, while Asia at 24.4% will exceed North America at 16.6%."

APC kiosks enable international travellers to rapidly clear passport control by entering their own immigration information. Automating this process via self-service kiosks decreases international arrival wait times by as much as 80% for kiosks users and 50% for all passengers.

The first generation of APC kiosks did not include biometrics and were available only to US and Canadian passport holders. Biometric APC kiosks extend this service to international travelers from 38 visa-waiver countries including Australia, Japan, Germany and the United Kingdom.

For additional insight and detailed APC kiosk market forecasts, see Acuity Market Intelligence's "The Automated Border Control Industry Report: Airport eGates and Kiosks" at www.acuity-mi.com/ABCair_Report.php .

About Acuity Market Intelligence ?Acuity Market Intelligence (http://www.acuity-mi.com) is an emerging technology strategy and research consultancy with a proven record of accurately anticipating biometric, identity, and eID market trends. Acuity consistently provides original, thought-provoking, accurate, and reliable insight and analysis. Acuity's data-driven approach provides critical market intelligence clients need to create and implement successful market development strategies that produce quantifiable results.

Contact:? Acuity Market Intelligence? +1 303 449 1897 ?

SOURCE Acuity Market Intelligence

ValidSoft's CEO Paul Burmester Joins "The Future of Secure, Mobile Authentication" Panel at Opus Research's Voice Biometrics Conference San Francisco 2014

ValidSoft's logo. (PRNewsFoto/ValidSoft)jwplayer.key="2kY/GKwZ2uQZmDlQ9VYArfZt2b4+KhHX3+DM4zisgtE=";LONDON and SAN FRANCISCO, May 14, 2014 /PRNewswire/ -- ValidSoft (www.validsoft.com), a global supplier of transaction authentication solutions utilized by banks, financial services companies and enterprise customers to secure and authorize transactions of all types, and an Elephant Talk Communications Corp. (NYSE MKT: ETAK) company, today announced that Paul Burmester, CEO of ValidSoft, is taking part in a panel discussion entitled "The Future of Secure, Mobile Authentication" at the Opus Research Voice Biometrics Conference held at the Fairmont Hotel San Francisco on May 14th and 15th. Opus Research's Voice Biometrics Conference ("VBC") is the premier global event tackling the issues and opportunities for phone-based security and multi-factor authentication.

VBC San Francisco 2014 showcases the ever-expanding set of current solutions and future opportunities for voice biometrics and phone-based technologies to support strong authentication and fraud prevention in contact centers, inside mobile devices and to enable secure commerce. Mr. Burmester is joined on the panel by a number of leading industry experts including Kayvan Alikhani, Senior Director of Technology, RSA, Emilio Martinez, Chief Executive Officer, Agnitio and Larry Koved of IBM Research.

"It's a very exciting time to be involved in 'Biometrics' as it enters the mainstream and user adoption accelerates, especially around the application of voice technology which leads the field in terms of ease of use," said Paul Burmester. "Today, we're focusing on integrating our Voice Biometric engine as part of a multi-factor authentication solution, balancing ease of use with security. Through events such as Opus' Voice Biometrics Conference, we have the ability to meet with our industry peers and work together to apply this technology towards new and exciting applications."

About ValidSoft UK Limited:
ValidSoft UK Limited ("ValidSoft") provides advanced mobile and cloud-security solutions. ValidSoft's custom-built sophisticated multi-factor authentication platform (SMART™) takes full advantage of telecommunications and includes a leading proprietary voice biometric engine. The platform combats electronic fraud and safeguards consumer privacy across internet, mobile banking, card, mobile and fixed line telecommunication channels. The company counts some of the largest financial institutions among its customers. ValidSoft is the only security software company in the world that has been granted three European Privacy Seals. Visit: www.validsoft.com.

About Elephant Talk Communications:
Elephant Talk Communications Corp. (NYSE MKT: ETAK), is a global provider of mobile proprietary Software Defined Network Architecture (ET Software DNA® 2.0) platforms for the telecommunications industry. The Company empowers Mobile Network Operators (MNOs), Mobile Virtual Network Operators (MVNOs), Enablers (MVNEs) and Aggregators (MVNAs) with a full suite of applications, superior industry expertise and high quality customer service without the need for substantial upfront investment. Elephant Talk counts several of the world's leading Mobile Network Operators amongst its customers, including Vodafone, T-Mobile, Zain and Iusacell. Visit: www.elephanttalk.com.

Media Contacts:

Investor Relations:
Steve Gersten
Elephant Talk Communications Corp.
+ 1 813 926 8920
Steve.Gersten@validsoft.com

Thomas Walsh
Alliance Advisors
+ 1 212 398 3486
twalsh@allianceadvisors.net

US: Michael Glickman
MWG CO
+1 917 596 1883
mike@mwco.net

Logo - http://photos.prnewswire.com/prnh/20120917/MM75492LOGO
Logo - http://photos.prnewswire.com/prnh/20120917/MM75872LOGO

SOURCE ValidSoft

SMI and Qualisys Connect Eye and Body Movements

BERLIN and TELTOW, Germany, May 13, 2014 /PRNewswire/ --

SensoMotoric Instruments (SMI) and Qualisys announce a plug and play integration of eye and motion tracking data which enables researchers to study embodied cognition, hand-eye coordination, disease, learning and performance

(Photo: http://photos.prnewswire.com/prnh/20140513/686477 )

SensoMotoric Instruments and Qualisys announce a plug&play integration of data recorded with SMI Eye Tracking Glasses and Qualisys motion capture systems. The combined analysis of eye and body movements enables researchers to better understand and assess visual motor integration. It helps behavioral psychologists and biomechanics researchers to study embodied cognition and to characterize hand-eye coordination - how it is learned, how it is optimized but also how it is affected by disease, ageing or injury. Sports scientists can make complex estimations of athletes' kinetics and performance in indoor and outdoor situations. And clinical researcher can use the information to advance diagnosis and rehabilitation. In the Qualisys Tracking Manager software, the 6D gaze data from SMI's leading wearable eye tracking technology is automatically synchronized with Qualisys motion capture samples and other external data e.g. from force plates. Motion and eye tracking video overlays and statistical data are available with a mouse click, revealing the interplay of visual perception and human motion.

To view a video of the SMI/Qualisys integration, click here: http://youtu.be/sNomkPAovUE

SMI Eye Tracking Glasses, SMI's leading wearable eye tracking technology, has gained the confidence of customers around the globe such as Stanford University, Max Planck Institute and the NASA, the French Institut National du Sport and the Occupational Skill Testing Authority of Guangdong in China and global players such as Google, Sony and Samsung. Instant setup and ease of use is paired with unmatched binocular eye tracking performance. SMI Eye Tracking Glasses can easily be equipped with snap-on optical tracking targets to stream 6D gaze data via the standard VRPN interface to a broad range of virtual reality and motion tracking applications.

Qualisys is a leading provider of motion capture technology and has a long history of supplying research, engineering and sports facilities with the tools and know-how of capturing and analysing movements. Qualisys offers a wide range of products and services, including its advanced motion capture platform, now with SMI eye tracking support.

Both SMI Eye Tracking Glasses and Qualisys motion capture systems are sunlight proven and can be employed in outdoor situations

Prof. Yvonne Delevoye-Turrell, Cognitive Psychology, Sports & Mental Health, at University of Lille, Research Unit on Cognitive and Affective Sciences: "As behavioral psychologists here in Lille our ultimate goal is to know more about the underlying reasons of human behavior. The integration of SMI and Qualisys technology allows us to measure the coordination of eye and body movements, to gain a better understanding of embodied cognition during normal but also abnormal interaction."

Dr. Daniel Lewkowicz, Post-Doctoral Fellow at University of Lille: "We used SMI Eye Tracking Glasses together with Qualysis Motion Tracking to examine how predictive gaze information is conveyed between two humans during real-time social interactions. It was one of the first attempts to combine both kinematics and portable eye-tracking devices in a true interactive face-to-face paradigm. Simultaneous recording of the kinematics of arm, hand and eye movements of two participants allowed us to study both joint action and joint attention in a truly interactive manner."

Magnus Berlander, CTO at Qualisys: "We decided to add eye tracking data to our motion capture software, Qualisys Track Manager, because it allows our customers to gain a better understanding of the interplay of visual information input, human motion, cognitive skills and learning. The available motion tracking interface of SMI Eye Tracking Glasses facilitated the integration and enabled us to come up with a plug&play solution easy to use even for non-technical users."

Dr. Arnd Rose, Product Manager, SensoMotoric Instruments: "Since its launch three years ago, our SMI Eye Tracking Glasses (ETG) have revolutionized insights into visual behaviour during truly mobile interaction. With the magnetic snap-on targets, our SMI Eye Tracking Glasses can easily be equipped for indoor and outdoor motion tracking studies. We are convinced that combined analysis of eye and body movements will add value to many fields which seek to understanding learning, advance clinical diagnosis and treatment and to improve performance. "

Meet SMI at:

International Congress of Sport Psychology, May 12-15, 2014, Nice, FR,

Vision Sciences Society Annual Meeting, May 16-21, 2014, St. Pete Beach, USA,

SMI Eye Tracking Roadshow: http://www.smivision.com/eyetracking_roadshow

###

Contact SMI: Stefanie Gehrke, Marcom Manager, stefanie.gehrke@smi.de
Contact Qualisys: Erik Westerstr?m, Sales Manager, erik.westerstrom@qualisys.se

Learn more about IrDive at the University of Lille North of France: http://www.scvis.fr/index.php?fr/static3/irdive

Learn more about SensoMotoric Instruments (SMI) athttp://www.smivision.com
Learn more about SMI Eye Tracking Glasses athttp://www.eyetracking-glasses.com

SMI on Facebook: http://www.facebook.com/smieyetracking
SMI on Twitter: http://www.twitter.com/smieyetracking
SMI on Flickr: http://www.flickr.com/smieyetracking
SMI on YouTube: http://www.youtube.com/smieyetracking

Learn more about Qualisys: http://www.qualisys.com

Qualisys on YouTube: http://www.youtube.com/QualisysAB
Qualisys on Twitter https://twitter.com/qualisysab/
Qualisys on Flickr: http://www.flickr.com/qualisys

SensoMotoric Instruments GmbH
Warthestrasse 21
14513 Teltow
Germany

Phone : +49(0)3328 3955-00
Fax : +49(0)3328 3955-99
WEB : http://www.smivision.com
E-Mail : info@smivision.de

Contact SMI: Stefanie Gehrke, Marcom Manager, stefanie.gehrke@smi.de
Contact Qualisys: Erik Westerstr?m, Sales Manager, erik.westerstrom@qualisys.se

SOURCE SensoMotoric Instruments GmbH

reade more...

Olivia Culpo, Former Miss Universe 2012, to Attend NXT-ID's Corporate Event for Wocket™ Smart Wallet at The Plaza Hotel on May 28th, 2014 New York City

SHELTON, Conn., May 14, 2014 /PRNewswire/ -- NXT-ID, Inc., (OTCQB: NXTD) a biometric authentication company focused on the growing m-commerce market, announces Olivia Culpo, former Miss Universe , Miss USA and Miss Rhode Island, will be the featured celebrity guest attending the first corporate launch event and press conference for its next generation, biometrically secure smart wallet, Wocket™.

The event will take place in New York City on May 28th at the Plaza Hotel from 3:00- 5:00 p.m.

The event will give consumers and media a first-hand look at the Wocket™ Smart Wallet, the Wocket™ Card, its new logo and brand images, new consumer video and new packaging. Following the event, consumers will be able to pre-order Wocket™ online by visiting: http://www.wocketwallet.com/.

The Wocket™ has recently been featured in online media, radio and television. On Friday May 9th on Channel 3, Eyewitness News (WFSB) in CT, CEO Gino Pereira gave viewers an inside look at how the Wocket™ becomes your own personal vault for securing your identity and your payment information.

Watch the full video: http://www.wfsb.com/story/25478720/wocket-smart-wallet-stores-information-for-hundreds-of-credit-and-gift-cards

The Company also announced earlier this week that the first CNBC advertisements will air on Squawk Box, Squawk on the Street and Street Signs beginning Wednesday, May 14th, 2014. Wocket™ is a next generation smart wallet designed to protect your identity and replace all the cards in your wallet, with no smart phone required. The Wocket works anywhere credit cards are accepted and only works with your biometric stamp of approval.

The Wocket product FAQ is available to consumers and media at http://www.wocketwallet.com/

The PLAZA May 28th event is limited to one hundred attendees consisting of media and shareholders. To attend please send requests to info@nxt-id.com or call 800 665 0411.

About Olivia Culpo:

Olivia Culpo was crowned Miss Universe 2012. She was the first American representative in 15 years to win the title. Earlier that year, representing the State of Rhode Island, Culpo also won the title of Miss USA.

About NXT-ID Inc. - Mobile Security for a Mobile World

NXT-ID, Inc.'s (OTCQB: NXTD) innovative MobileBio™ solution mitigates consumer risks associated with mobile computing, m-commerce and smart OS-enabled devices. The company is focused on the growing m-commerce market, launching its innovative MobileBio™ suite of biometric solutions that secure consumers' mobile platforms led by the Wocket™ ; a next generation smart wallet designed to replace all the cards in your wallet, no smart phone required. The Wocket works anywhere credit cards are accepted and only works with your biometric stamp of approval. http://www.thewocket.com/ and http://www.wocketwallet.com/

NXT-ID's wholly owned subsidiary, 3D-ID LLC, is engaged in biometric identification has 22 licensed patents in the field of 3D facial recognition http://www.nxt-id.com/, http://3d-id.net/

Forward-Looking Statements for NXT-ID

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company's business strategy. The Company's actual results could differ materially from those anticipated in these forward- looking statements as a result of various factors. Such risks and uncertainties include, among other things, our ability to establish and maintain the proprietary nature of our technology through the patent process, as well as our ability to possibly license from others patents and patent applications necessary to develop products; the availability of financing; the Company's ability to implement its long range business plan for various applications of its technology; the Company's ability to enter into agreements with any necessary marketing and/or distribution partners; the impact of competition, the obtaining and maintenance of any necessary regulatory clearances applicable to applications of the Company's technology; and management of growth and other risks and uncertainties that may be detailed from time to time in the Company's reports filed with the Securities and Exchange Commission.

Contact:

Corporate info: info@nxt-id.com

Investor Inquiries:

Kirin Smith, ProActive Capital Group

Direct: 646 863 6519

ksmith@proactivecrg.com

Media: 800 665-0411

SOURCE NXT-ID, Inc.

RELATED LINKS
http://www.wocketwallet.com

reade more...

Peer Review Studies Find Decipher® Genomic Test Significantly Changes Postoperative Treatment Recommendations for Prostate Cancer Patients and Increases Confidence in Treatment Decisions

SAN DIEGO, May 14, 2014 /PRNewswire/ -- GenomeDx Biosciences today announced data from two new clinical utility studies demonstrating that Decipher® Prostate Cancer Classifier significantly changed treatment decisions and increased confidence in treatment decision-making for men considering adjuvant therapy following prostate surgery. The studies are being published in upcoming issues of the journals Current Medical Research and Opinion (CMRO) and the British Journal of Urology International (BJUI), respectively.

"The American Urological Association has issued clinical guidelines recommending adjuvant radiation therapy to all prostate cancer patients with adverse pathology after surgery, despite that most men in this group did not develop metastasis or die of prostate cancer," noted John Hornberger, M.D., Principal of Cedar Associates, LLC, adjunct faculty at Stanford and senior author on the study published in CMRO. "By providing a more objective, individualized estimate of metastasis risk based on a quantitative laboratory assay, adoption of the Decipher prostate cancer test may reduce inappropriate or inconsistent use of adjuvant treatment in this population."

In the PRO-ACT study published in CMRO, 15 board-certified, community-based urologists who had ordered the Decipher test to inform management of their current patients were asked to provide treatment recommendations before and after receiving their patients' Decipher test results and then complete a decision conflict scale, a measure designed to assess confidence in treatment recommendations. Prior to receiving the Decipher test results, physicians were asked to make treatment decisions based on clinical risk factors such as Gleason score and tumor stage. Following the receipt of Decipher results, physicians changed their treatment recommendations for 30.8 percent of patients (95% CI, 23-39%). Among the 102 patients for whom observation was initially recommended, physicians changed recommendations to adjuvant radiation for 18 of those patients. Conversely, 17 of the 40 patients who were initially slated for adjuvant radiation saw recommendations change to observation. The genomic information provided by Decipher test results significantly influenced which patients were recommended adjuvant treatment (p<0.001). In addition, decisional conflict with regard to physicians' decision to treat with adjuvant radiation therapy was significantly less with the use of Decipher results than without (p<0.0001).

"Making secondary treatment decisions after our patients have had surgery is not cut and dry. Most men who do not need additional treatment would prefer to avoid the side effects," said Ketan Badani, M.D., urologic oncologist at Columbia University in New York. "The ASSESS-D study clearly demonstrates that adding a test like Decipher, that gives physicians a readout of the genomic fingerprint of a patient's prostate cancer and provides a more precise measure of the biologic risk of developing metastasis, can help physicians make more appropriate treatment decisions, and be more confident in those decisions."

In the ASSESS-D study, a multi-center, prospective decision impact study published in BJUI, 51 community urologists reviewed and provided adjuvant treatment recommendations for randomly selected patient cases considered by clinical practice guidelines to be high risk for metastasis following prostate surgery. Overall, 31 percent (95% CI: 27-35%) of treatment recommendations were changed after reviewing the Decipher results. Among adjuvant radiation therapy recommendations without Decipher results, 40% (n=77) changed to observation (95% CI: 33-47%) following knowledge of Decipher results. For patient cases recommended for observation, 13% (n=38) (95% CI: 9%-17%) were changed to adjuvant radiation therapy with Decipher. Case histories with low Decipher results were recommended observation 81% of the time (n=276), while for those with high Decipher results, 65% were recommended for treatment (n=118, p<0.0001). Treatment intensity was strongly correlated with the Decipher-predicted probability of metastasis (p<0.001) and the Decipher test was the dominant risk factor driving decisions in multivariable analysis (OR=8.6, 95% CI: 5.3-14.3%, p<0.0001).

About Decipher

The Decipher® Prostate Cancer Classifier directly measures a patient's biological risk of developing metastatic prostate cancer. By assessing the activity of multiple genomic markers associated with metastatic disease, Decipher provides information about the aggressiveness of a patient's tumor - information distinct from that provided by PSA and other clinical risk factors. Decipher continues to demonstrate that it can accurately predict aggressive disease and help physicians make more informed treatment decisions for men with prostate cancer.

Decipher is covered by multiple private insurance plans and is available to eligible US patients through their physicians. To learn more about ordering the Decipher test please visit www.deciphertest.com.

About GenomeDx Biosciences

GenomeDx Biosciences is focused on transforming patient management by putting usable genomic information in the hands of patients and their physicians. GenomeDx has developed the Decipher® Prostate Cancer Classifier, the first and only commercially available genomic test that predicts the risk of developing metastatic prostate cancer independently of PSA and other conventional risk assessment tools. GenomeDx is based in San Diego, California and Vancouver, British Columbia. To learn more visit www.genomedx.com

SOURCE GenomeDx Biosciences

Global Biometrics Technology (Face, Hand geometry, Voice, Signature, Iris, AFIS, Non-AFIS and Others) Market - Forecast to 2019

DUBLIN, May 9, 2014 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/xt73hk/biometrics) has announced the addition of the "Biometrics Technology Market - Global Industry Analysis Size Share Growth Trends and Forecast 2013 - 2019" report to their offering.

http://photos.prnewswire.com/prnh/20130307/600769

Biometrics helps in verifying the identity of a person based on physiological or behavioral characteristics. Specifically, traditional authentication methods such as magnetic cards, personal identification cards, passwords or keys are vulnerable to attacks and can be easily stolen. Biometrics technology identifies an individual on the basis of their fingerprints, face, signature, DNA, iris, typing rhythms etc and provides convenient and secure authentication.

With the thriving Internet-based commerce such as online banking and rising need for precise verification while accessing accounts, biometrics technology is considered to be the most convenient and simplest solution. Its permanent, measurable, universal and unique features ensure high level of information security and these are the key factors which would help to contribute to its growth by 2019.

In 2012, among all application segments, the non-AFIS segment dominated the biometrics market. This was due to its cost effectiveness and user friendliness. Additionally, non-AFIS systems are more flexible and convenient as compared to other recognition systems and require low maintenance. However, iris recognition systems have an enormous untapped market as an emergent technology with increasing adoption mostly in the areas of access control and high-end security applications.

Key Topics Covered:

Chapter 1 Preface

Chapter 2 Executive summary

Chapter 3 Global Biometrics technology market overview

Chapter 4 Global Biometrics technology systems market, by Application Type 2013 - 2019

Chapter 5 Global Biometrics technology market, by End Users 2013 - 2019

Chapter 6 Global Biometrics technology market, by region 2013 - 2019

Chapter 7 Company profiles

Companies Mentioned:

3M Cogent, Inc. Accu-Time Systems, Inc. BIO-Key International, Inc. Cognitec Systems, GmbH Daon, Inc. DigitalPersona, Inc. Fujitsu Limited IDTECK, IrisGuard, Inc. Lumidigm, Inc. Morpho SA (Safran) NEC Corporation RCG Holdings, Ltd. Siemens AG Suprema, Inc. For more information visit http://www.researchandmarkets.com/research/xt73hk/biometrics

Media Contact: Laura Wood, +353-1-481-1716, press@researchandmarkets.net

SOURCE Research and Markets

RELATED LINKS
http://www.researchandmarkets.com

reade more...

L'ETS annonce une identification biométrique de la voix avancée

ETS logo. (PRNewsFoto/Educational Testing Service)jwplayer.key="2kY/GKwZ2uQZmDlQ9VYArfZt2b4+KhHX3+DM4zisgtE=";-- Brevet en instance pour la nouvelle mesure de sécurité de tests internationaux pour les tests TOEFL® et TOEIC®

PRINCETON, New Jersey, 9 mai 2014 /PRNewswire/ -- L'ETS a annoncé aujourd'hui qu'un nouveau renforcement important de la sécurité, conçu pour consolider la position du programme TOEFL® de la société comme l'un des tests de langue anglaise les plus sécurisés dans le monde, fait sa sortie mondiale. L'identification biométrique de la voix, l'une des avancées les plus significatives en matière de sécurité dans le secteur des tests depuis de nombreuses années, fait sa sortie le 8 février 2014 dans les 130 pays dans lesquelles les étudiants subissent le test TOEFL chaque année.

Logo - http://photos.prnewswire.com/prnh/20120110/DC33419LOGO

Le programme TOEFL a commencé le pilotage du logiciel, qui est conçu pour identifier les soupçons d'usurpation d'identité, en mai 2012, et le logiciel a fait sa sortie aujourd'hui à l'échelle mondiale dans le cadre de la présélection pour tous les postulants subissant le test TOEFL dans le monde entier. L'ETS a actuellement un brevet en instance pour l'utilisation du logiciel d'identification biométrique de la voix à cet effet et le test TOEFL est le seul test de compétence dans la langue anglaise qui utilise cette mesure de sécurité avancée dans le monde entier.

« La phase pilote du logiciel d'identification biométrique de la voix s'est avérée un atout important dans l'identification de soupçons d'usurpation d'identité et il permet à l'ETS d'annuler les résultats avant qu'ils ne soient relevés », a commenté David Hunt, vice-président directeur de la division éducation planétaire et des effectifs mondiaux chez l'ETS. « La sécurité est une priorité absolue chez l'ETS et nous sommes fiers d'avoir mis en place cette mesure de sécurité, la meilleure dans sa catégorie, pour notre test TOEFL. Les résultats valides dépendent d'une administration sécurisée et ce nouvel outil puissant va nous aider à garantir précisément cela ».

Le progiciel sophistiqué d'identification biométrique de la voix a été développé par une société qui offre des solutions comparables pour les organismes dans les opérations bancaires, d'application de la loi et dans les industries des soins de santé. L'ETS a également élevé l'importance de sa ligne réservée à l'intention des dénonciateurs sur sa page d'accueil afin d'encourager toute personne qui soupçonne des activités frauduleuses à faire connaître ses préoccupations à la société.

« L'utilisation de la technologie d'identification biométrique de la voix est là encore un autre exemple de la raison pour laquelle nous, chez The University of Texas à Austin, considérons que le TOEFL iBT® est la meilleure mesure de compétence de l'anglais actuellement en disponibilité », déclare Robert Watkins, directeur adjoint du Centre des admissions internationales et aux études supérieures à l'UTA.

L'ETS envisage de prolonger l'identification biométrique de la voix pour prendre en charge le programme de TOEIC® cette année. Plus de renseignements concernant les processus de sécurité de prévention et de détection du test TOEFL sont à votre disposition en consultant www.ets.org/toefl/institutions/about/security.

A propos de l'ETS
Chez l'ETS, nous faisons progresser la qualité et l'équité de l'éducation offerte aux personnes dans le monde entier en créant des évaluations fondées sur des recherches rigoureuses. L'ETS est au service des individus, des établissements d'enseignement et des agences gouvernementales en leur offrant des solutions personnalisées pour la délivrance de certificats d'aptitude pédagogique, l'apprentissage de l'anglais et l'enseignement au niveau primaire, secondaire et postsecondaire ainsi qu'en menant des recherches sur l'éducation, des analyses et des études sur les politiques éducatives. Fondée sous forme d'organisation à but non lucratif en 1947, l'ETS élabore, administre et évalue plus de 50 millions de tests chaque année — dont les tests TOEFL® et TOEIC® , les tests GRE® et les évaluations The Praxis Series® — dans plus de 9 000 lieux répandus dans plus de 180 pays dans le monde entier. www.ets.org

SOURCE Educational Testing Service